MORGAN STANLEY PLC/CALL/ROCHE GS/310/0.01/21.06.24 Share Price

Warrant

DE000MD8V3N7

Market Closed - Börse Stuttgart 17:57:45 31/05/2024 BST
0.001 EUR -.--% Intraday chart for MORGAN STANLEY PLC/CALL/ROCHE GS/310/0.01/21.06.24
6 months-90.91%
Current year-92.86%
Date Price Change
31/05/24 0.001 -.--%
30/05/24 0.001 -.--%
29/05/24 0.001 -.--%
28/05/24 0.001 -.--%
27/05/24 0.001 -.--%

Delayed Quote Börse Stuttgart

Last update May 31, 2024 at 05:57 pm

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying ROCHE HOLDING AG
Issuer Morgan Stanley
WKN MD8V3N
ISINDE000MD8V3N7
Date issued 03/10/2022
Strike 310 CHF
Maturity 21/06/2024 (19 Days)
Parity 100 : 1
Emission price 0.53
Emission volume N/A
Settlement Barausgleich
Currency EUR

Technical Indicators

Highest since issue 0.48
Lowest since issue 0.001
Spread 0.039
Spread %97.50%

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
231 CHF
Average target price
277.5 CHF
Spread / Average Target
+20.14%
Consensus